CTKB — Cytek Biosciences Cashflow Statement
0.000.00%
Last trade - 00:00
- $669.36m
- $395.41m
- $193.02m
- 78
- 29
- 48
- 50
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | PROSPECTUS | PROSPECTUS | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Net Income/Starting Line | -16.8 | 19.4 | 3.03 | 2.48 | -12.1 |
Depreciation | |||||
Non-Cash Items | 1.61 | 2.68 | 8.72 | 22.7 | 21.6 |
Unusual Items | |||||
Equity in Net Earnings/Losses | |||||
Other Non-Cash Items | |||||
Changes in Working Capital | 1.16 | -7.54 | -8.36 | -39.9 | -10.2 |
Change in Accounts Receivable | |||||
Change in Inventories | |||||
Change in Prepaid Expenses | |||||
Change in Accounts Payable | |||||
Change in Accrued Expenses | |||||
Change in Other Liabilities | |||||
Cash from Operating Activities | -13.7 | 15.2 | 4.63 | -12.2 | 5.28 |
Capital Expenditures | -0.973 | -1.55 | -4.36 | -9.87 | -4.83 |
Purchase of Fixed Assets | |||||
Purchase / Acquisition of Intangibles | |||||
Other Investing Cash Flow Items | — | — | -16.6 | -46 | -89.1 |
Acquisition of Business | |||||
Sale of Business | |||||
Sale/Maturity of Investment | |||||
Purchase of Investments | |||||
Cash from Investing Activities | -0.973 | -1.55 | -21 | -55.9 | -93.9 |
Financing Cash Flow Items | — | — | — | -0.209 | -0.419 |
Other Financing Cash Flow | |||||
Net Issuance / Retirement of Stock | |||||
Net Issuance / Retirement of Debt | |||||
Cash from Financing Activities | 0.093 | 123 | 214 | 5.51 | -41.8 |
Foreign Exchange Effects | |||||
Beginning Cash Balance | |||||
Ending Cash Balance | |||||
Net Change in Cash | -14.7 | 136 | 198 | -65.1 | -132 |